1 Min Read
Sept 29 (Reuters) - Astrazeneca Plc
* U.S. FDA has approved a blood-based companion diagnostic for Tagrisso (osimertinib) Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.